Action Pharma A/S - Product Pipeline Review - 2012

Global Markets Direct, July 2012, Pages: 29

Action Pharma A/S – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Action Pharma A/S - Product Pipeline Review - 2012” provides data on the Action Pharma A/S’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Action Pharma A/S’s corporate website, SEC filings, investor presentations and featured press releases, both from Action Pharma A/S and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Action Pharma A/S - Brief Action Pharma A/S overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Action Pharma A/S human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Action Pharma A/S with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Action Pharma A/S’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Action Pharma A/S’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Action Pharma A/S in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Action Pharma A/S’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Action Pharma A/S.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Action Pharma A/S and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Action Pharma A/S; Action Pharma A/S - Key Therapeutics; Action Pharma A/S - Pipeline Overview and Promising Molecules; Action Pharma A/S - News; Action Pharma A/S - Latest Updates; Action Pharma A/S - Pipeline; Action Pharma A/S - Discontinued/Dormant Projects

2
List of Tables 3
List of Figures 3
Action Pharma A/S Snapshot 4
Action Pharma A/S Overview 4
Key Information 4
Key Facts 4
Action Pharma A/S – Research and Development Overview 5
Key Therapeutic Areas 5
Action Pharma A/S – Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products – Monotherapy 8
Action Pharma A/S – Pipeline Products Glance 9
Action Pharma A/S – Early Stage Pipeline Products 9
Pre-Clinical Products/Combination Treatment Modalities 9
Action Pharma A/S – Drug Profiles 10
AP405 10
Product Description 10
Mechanism of Action 10
R&D Progress 10
Action Pharma A/S – Pipeline Analysis 11
Action Pharma A/S – Pipeline Products by Therapeutic Class 11
Action Pharma A/S – Pipeline Products By Target 12
Action Pharma A/S – Pipeline Products by Route of Administration 13
Action Pharma A/S – Pipeline Products By Mechanism of Action 14
Action Pharma A/S - Dormant Projects 15
Action Pharma A/S – Locations And Subsidiaries 16
Head Office 16
Financial Deals Landscape 17
Action Pharma A/S, Deals Summary 17
Action Pharma A/S, Pharmaceuticals & Healthcare, Deal Details 18
Venture Financing 18
Action Pharma Secures $6.1 Million In Series C Venture Financing 18
Action Pharma Secures $22 Million In Series D Financing Round 20
Action Pharma Secures $7.6 Million In Venture Financing 22
Action Pharma Secures $3.11 Million In Second Round Of Financing 24
Asset Transactions 26
Abbott Labs Acquires AP214 From Action Pharma For $110 Million 26
Appendix 28
Methodology 28
Coverage 28
Secondary Research 28
Primary Research 28
Expert Panel Validation 28
Contact Us 29
Disclaimer 29

List of Tables
Action Pharma A/S, Key Information 4
Action Pharma A/S, Key Facts 4
Action Pharma A/S – Pipeline by Indication, Select 6
Action Pharma A/S – Pipeline by Stage of Development, Select 7
Action Pharma A/S – Monotherapy Products in Pipeline, Select 8
Action Pharma A/S – Pre-Clinical, Select 9
Action Pharma A/S – Pipeline By Therapeutic Class, Select 11
Action Pharma A/S - Pipeline By Target, Select 12
Action Pharma A/S – Pipeline By Route of Administration, Select 13
Action Pharma A/S – Pipeline Products By Mechanism of Action, Select 14
Action Pharma A/S - Dormant Developmental Projects,Select 15
Action Pharma A/S, Deals Summary 17
Action Pharma Secures $6.1 Million In Series C Venture Financing 18
Action Pharma Secures $22 Million In Series D Financing Round 20
Action Pharma Secures $7.6 Million In Venture Financing 22
Action Pharma Secures $3.11 Million In Second Round Of Financing 24
Abbott Labs Acquires AP214 From Action Pharma For $110 Million 26

List of Figures
Action Pharma A/S – Pipeline by Indication, Select 6
Action Pharma A/S – Pipeline by Stage of Development, Select 7
Action Pharma A/S – Monotherapy Products in Pipeline, Select 8
Action Pharma A/S – Pipeline By Therapeutic Class, Select 11
Action Pharma A/S - Pipeline By Target, Select 12
Action Pharma A/S - Pipeline Products By Mechanism of Action, Select 14

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Scientific Games Corporation - Company Analysis
• eBay - Strong Execution
• Ixia - Company Analysis
• Amazon - Point of Realization in 2013?
• SunGard - Profile - US
• Insight into Samsung Electronics' Notebook PC Business Model
• ON Vendor Profile: Ciena